XETRA · MRK.DE
Merck KGaA
€151.55+€1.25 (+0.83%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.36% below the high.
Loading market information…
XETRA · T5O.DE · EUR
Stock price, earnings
Quote as of Aug 9, 2024, 03:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
CytoTools AG’s quoted price sits in the lower half of its reported 52-week range, 90.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CytoTools AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
German biotechnology company CytoTools AG, established in 2000, specializes in developing innovative, disease-modifying therapies. The company leverages its unique portfolio of proprietary small-molecule compounds and biological agents to address unmet medical needs across various therapeutic domains, including dermatology, cardiovascular health, urology, and oncology. At the forefront of its clinical efforts is DermaPro, which has successfully completed Phase III trials for diabetic foot ulcers (DFU) in India. This same product is currently undergoing Phase III trials for DFU in Europe and is also in Phase II/III studies for venous leg ulcers (VLU) in Germany, where it additionally functions as an anti-infective. Beyond this lead product, CytoTools' development pipeline features Utisept, a urological medical device designed for bladder flushing in urinary tract infections, and Derma MP, another therapy aimed at treating venous leg ulcers in Europe. In earlier stages, CardioClean is a preclinical candidate targeting conditions such as restenosis, diabetes, and carotid stenosis, while Cancer T17-n is an oncology project focused on cancer treatment in Europe. Furthermore, CytoTools has forged a collaboration with Activoris Medizintechnik GmbH to develop an inhalation therapy specifically for viral infections like COVID-19 and influenza. The company is headquartered in Darmstadt, Germany.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:12 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€151.55+€1.25 (+0.83%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.36% below the high.
€49.86+€1.90 (+3.96%)
Bayer Aktiengesellschaft’s quoted price sits in the upper half of its reported 52-week range, 7.55% below the high.
€43.10+€0.21 (+0.49%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.28% below the high.
€6.18+€0.08 (+1.31%)
Viscom AG’s quoted price sits in the upper half of its reported 52-week range, 9.12% below the high.
€2.79€0.00 (0.0%)
FamiCord AG’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
€3.04-€0.01 (-0.33%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 41.31% below the high.
€0.99+€0.02 (+1.64%)
Syzygy AG’s quoted price sits in the lower half of its reported 52-week range, 44.74% below the high.
€0.05€0.00 (0.0%)
Paion AG’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
